Vistagen Therapeutics Inc (NASDAQ:VTGN) price on Thursday, July 03, fall -1.96% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $2.0.
A look at the stock’s price movement, the close in the last trading session was $2.04, moving within a range at $1.99 and $2.05. The beta value (5-Year monthly) was 0.687. Turning to its 52-week performance, $4.21 and $1.90 were the 52-week high and 52-week low respectively. Overall, VTGN moved -16.32% over the past month.
Vistagen Therapeutics Inc’s market cap currently stands at around $58.31 million, with investors looking forward to this quarter’s earnings report slated for on 2025-Jun-02.
Turning to the stock’s technical picture we see that short term indicators suggest on average that VTGN is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
3 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 2 recommend VTGN as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
VTGN’s current price about -7.61% and -12.50% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.12, while 7-day volatility ratio is 4.42% and 6.26% in the 30-day chart. Further, Vistagen Therapeutics Inc (VTGN) has a beta value of 0.37. Analysts have given the company’s stock an average 52-week price target of $6, forecast between a low of $6 and high of $6. Looking at the price targets, the low is -200.0% off current price level while to achieve the yearly target high, price needs to move -200.0%. Nonetheless, investors will most likely welcome a -200.0% jump to $6 which is the analysts’ median price.
If we refocus on Vistagen Therapeutics Inc (NASDAQ:VTGN), historical trading data shows that trading volumes averaged 0.2 over the past 10 days and 152.25K over the past 3 months. The company’s latest data on shares outstanding shows there are 28.32 million shares.
The 9.53% of Vistagen Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 45.99% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.48 million on 2025-06-13, giving us a short ratio of 2.92. The data shows that as of 2025-06-13 short interest in Vistagen Therapeutics Inc (VTGN) stood at 241.0 of shares outstanding, with shares short falling to 0.52 million registered in 2025-05-15. Current price change has pushed the stock -43.98% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the VTGN stock continues to rise going into the next quarter.
